Skip to main navigation menu Skip to main content Skip to site footer
Brazilian Journal of Clinical Medicine and Review

Letter to Editor

Vol. 2 No. 4 (2024): October/December - 2024

From Myelodysplastic Syndrome to Myelodysplastic Neoplasm: The Impact of WHO's Reclassification on MDS Research

DOI
https://doi.org/10.52600/2965-0968.bjcmr.2024.2.4.97-99
Submitted
May 14, 2024
Published
2024-05-14

Abstract

This letter addresses the challenges posed by the recent reclassification of Myelodysplastic Syndromes (MDS) to Myelodysplastic Neoplasm (maintaining the acronym MDS) by the World Health Organization (WHO). Despite the clinical and scientific justification for this change, the adoption of the new terminology in the research community has been slow, leading to decreased visibility and citation of studies using the updated nomenclature. Here, it was proposed a gradual transition where both terminologies are used simultaneously in research articles to maintain research visibility while educating the medical community about the new terminology. Furthermore, it is suggested that major databases and search engines update their algorithms to link both terms, ensuring comprehensive search results. The role of international medical societies and scientific journals in promoting the use of the new terminology is also emphasized.

References

  1. Prakash, S.; Arber, D.A.; Bueso-Ramos, C.; Hasserjian, R.P.; Orazi, A. Advances in Myelodysplastic/Myeloproliferative Neo-plasms. Virchows Archiv 2023, 482, 69–83, doi:10.1007/s00428-022-03465-7.
  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 Aug;33(4):451-8. doi: 10.1111/j.1365-2141.1976.tb03563.x. PMID: 188440.
  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189-99. PMID: 6952920.
  4. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classi-fication of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22. PMID: 35732831; PMCID: PMC9252913.
  5. Goes JVC, Viana MA, Sampaio LR, Cavalcante CBA, Melo MML, de Oliveira RTG, Borges DP, Gonçalves PG, Pinheiro RF, Ribeiro-Junior HL. Gene expression patterns of Sirtuin family members (SIRT1 TO SIRT7): Insights into pathogenesis and prognostic of Myelodysplastic neoplasm. Gene. 2024 Apr 3;915:148428. doi: 10.1016/j.gene.2024.148428. Epub ahead of print. PMID: 38575099.
  6. Sampaio LR, Viana MA, de Oliveira VS, Ferreira BV, Melo MML, de Oliveira RTG, Borges DP, Magalhãesa SMM, Pinheiro RF. High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms. Hematol Transfus Cell Ther. 2023 Jun 5:S2531-1379(23)00100-1. doi: 10.1016/j.htct.2023.05.002. Epub ahead of print. PMID: 37543491.
  7. Ribeiro Junior HL, Gonçalves PG, Moreno DA, Goes JVC, de Oliveira RTG, Montefusco-Pereira CV, Komoto TT, Pinheiro RF. Discrepancy in transcriptomic profiling between CD34 + stem cells and primary bone marrow cells in myelodysplastic ne-oplasm. Leuk Res. 2023 Jun;129:107071. doi: 10.1016/j.leukres.2023.107071. Epub 2023 Mar 29. PMID: 37004280.